Meeting Banner
Abstract #3441

31P MRSI as an Early Indicator of Response to Radiation Treatment in Liver Cancer

Tony Clevenger1, 2, Anshuman Panda, 13, Scott Jones1, 2, Kumar Sandrasegaran2, Higinia Cardenes4, Ulrike Dydak1, 2

1School of Health Sciences, Purdue University, West Lafayette, IN, United States; 2Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, United States; 3Department of Radiology, Mayo Clinic Arizona, Scottsdale, AZ, United States; 4Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, United States

Phosphorous-31 (31P) MRSI has been shown to distinguish well between healthy and malignant liver tissue. The current RECIST criteria to monitor response of hepatocellular cancer (HCC) to radiation therapy often take up to 6 months to show results, and can be ambiguous or erroneous. Results are presented of our pilot study showing that 31P MRSI in HCC patients can predict treatment response within one month of radiation therapy. These results indicate that 31P MRSI has potential as an early indicator of response to radiation therapy.